ReviewCell communication and signaling : CCS2026
Metabolic reprogramming of CAR-T cells: a multi-pronged strategy to conquer the immunosuppressive tumor microenvironment.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CAR-T cell therapy has demonstrated remarkable success in hematologic malignancies, yet its application in solid tumors continues to face formidable challenges posed by metabolic dysregulation within the tumor microenvironment (TME). The TME impairs CAR-T cell effector function and persistence through mechanisms such as nutrient deprivation (e.g., glucose scarcity), disrupted lipid metabolism, and the accumulation of immunosuppressive metabolites (e.g., kynurenine). This review systematically outlines multidimensional strategies to enhance CAR-T cell efficacy through metabolic reprogramming: in glucose metabolism, approaches such as ex vivo metabolic priming, genetic engineering, and pharmacological modulation improve glucose uptake and utilization; in lipid metabolism, domain selection, gene modification, and combinatorial interventions optimize fatty acid oxidation and memory phenotype maintenance; in amino acid metabolism, engineering and pharmacological inhibition alleviate essential amino acid depletion and metabolite-induced immunosuppression. Collectively, these strategies endow CAR-T cells with greater metabolic adaptability, laying the foundation for breakthroughs in tumor therapy. Looking ahead, multi-pathway synergistic interventions, dynamically controllable metabolic regulation, and personalized metabolic adaptation are poised to become central pillars in the development of next-generation CAR-T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.